Boston Scientific is paying $150m up front and another $125m in milestone payments over four years to acquire nVision.

nVision has developed Mako 7 device, which uses patented microcatheter technology to access and collect cells from the fallopian tube during a minimally-invasive hysteroscopic procedure.

Claimed to be the first and only device secured approval from the US Food and Drug Administration, Mako 7 helps in earlier diagnosis of ovarian cancer.

According to nVision, the cell collection device showed the ability to navigate and access the fallopian tubes and collect cell samples that are enough for cytological assessment in a clinical trial consisting of 40 patients and 80 fallopian tubes.

Boston Scientific intends to carry out additional clinical research with the nVision device to further demonstrate how the cells it collects from the fallopian tubes can be used to depict a diagnosis prior to surgery and assist in the decision-making process for women at increased risk for ovarian cancer.

Boston Scientific MedSurg president and executive vice president Dave Pierce said: "We estimate the near-term market opportunity to be $500 million with the potential to grow to $2 billion as this device is used by more gynecologists to help even more women.

“We are committed to expanding our women's health portfolio and driving clinical research that will help deliver innovative options for the prevention and treatment of gynecological cancer."

nVision founder and CEO Surbhi Sarna said: "I am proud of our achievements in advancing efforts to help with the early detection of ovarian cancer and look forward to working with Boston Scientific to move this technology forward."

Earlier this month, Boston Scientific purchased remaining stake in US-based Securus Medical Group in a transaction worth about $50m.

Since 2016, Boston Scientific has been an investor in Securus Medical.

Image: Boston Scientific's Corporate Headquarters in Marlborough, Massachusetts. Photo: courtesy of Boston Scientific Corporation.